nodes	percent_of_prediction	percent_of_DWPC	metapath
Lofexidine—HTR1A—Parkinson's disease	0.931	1	CbGaD
Lofexidine—HTR1A—telencephalic ventricle—Parkinson's disease	0.0047	0.207	CbGeAlD
Lofexidine—ADRA2A—peripheral nervous system—Parkinson's disease	0.00267	0.117	CbGeAlD
Lofexidine—HTR1A—hindbrain—Parkinson's disease	0.00222	0.0978	CbGeAlD
Lofexidine—HTR1A—brainstem—Parkinson's disease	0.00127	0.0561	CbGeAlD
Lofexidine—HTR1A—forebrain—Parkinson's disease	0.00123	0.0541	CbGeAlD
Lofexidine—HTR1A—cardiovascular system—Parkinson's disease	0.00104	0.0458	CbGeAlD
Lofexidine—ADRA2A—forebrain—Parkinson's disease	0.000861	0.0379	CbGeAlD
Lofexidine—Clonidine—CYP2D6—Parkinson's disease	0.000858	0.583	CrCbGaD
Lofexidine—HTR1A—midbrain—Parkinson's disease	0.000811	0.0357	CbGeAlD
Lofexidine—HTR1A—spinal cord—Parkinson's disease	0.000791	0.0349	CbGeAlD
Lofexidine—HTR1A—head—Parkinson's disease	0.000703	0.031	CbGeAlD
Lofexidine—HTR1A—nervous system—Parkinson's disease	0.000667	0.0294	CbGeAlD
Lofexidine—HTR1A—central nervous system—Parkinson's disease	0.000642	0.0283	CbGeAlD
Lofexidine—HTR1A—cerebellum—Parkinson's disease	0.000628	0.0276	CbGeAlD
Lofexidine—ADRA2A—medulla oblongata—Parkinson's disease	0.000622	0.0274	CbGeAlD
Lofexidine—Clonidine—ABCB1—Parkinson's disease	0.000613	0.417	CrCbGaD
Lofexidine—ADRA2A—midbrain—Parkinson's disease	0.000569	0.025	CbGeAlD
Lofexidine—ADRA2A—spinal cord—Parkinson's disease	0.000555	0.0244	CbGeAlD
Lofexidine—HTR1A—brain—Parkinson's disease	0.00051	0.0225	CbGeAlD
Lofexidine—ADRA2A—head—Parkinson's disease	0.000493	0.0217	CbGeAlD
Lofexidine—ADRA2A—nervous system—Parkinson's disease	0.000467	0.0206	CbGeAlD
Lofexidine—ADRA2A—central nervous system—Parkinson's disease	0.00045	0.0198	CbGeAlD
Lofexidine—ADRA2A—cerebellum—Parkinson's disease	0.00044	0.0194	CbGeAlD
Lofexidine—ADRA2A—brain—Parkinson's disease	0.000357	0.0157	CbGeAlD
Lofexidine—ADRA2A—Hemostasis—MERTK—Parkinson's disease	0.000226	0.00506	CbGpPWpGaD
Lofexidine—ADRA2A—Hemostasis—DOCK3—Parkinson's disease	0.000226	0.00506	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—GPR37—Parkinson's disease	0.000225	0.00505	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	0.000222	0.00497	CbGpPWpGaD
Lofexidine—ADRA2A—G alpha (i) signalling events—PDYN—Parkinson's disease	0.000219	0.00491	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—ADORA2A—Parkinson's disease	0.000204	0.00458	CbGpPWpGaD
Lofexidine—ADRA2A—Hemostasis—DGKQ—Parkinson's disease	0.000201	0.00451	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—GRM4—Parkinson's disease	0.000195	0.00436	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—MAOA—Parkinson's disease	0.000193	0.00432	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PENK—Parkinson's disease	0.00019	0.00427	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—BDNF—Parkinson's disease	0.000186	0.00417	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—PENK—Parkinson's disease	0.000184	0.00414	CbGpPWpGaD
Lofexidine—HTR1A—G alpha (i) signalling events—DRD3—Parkinson's disease	0.000179	0.00401	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.000175	0.00393	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PDYN—Parkinson's disease	0.000174	0.00391	CbGpPWpGaD
Lofexidine—ADRA2A—Regulation of insulin secretion—INS—Parkinson's disease	0.000173	0.00387	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	0.000171	0.00384	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—PDYN—Parkinson's disease	0.000169	0.00378	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	0.000166	0.00372	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—NGF—Parkinson's disease	0.000165	0.0037	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—DGKQ—Parkinson's disease	0.000162	0.00363	CbGpPWpGaD
Lofexidine—HTR1A—G alpha (i) signalling events—DRD2—Parkinson's disease	0.000162	0.00363	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADORA2A—Parkinson's disease	0.000161	0.0036	CbGpPWpGaD
Lofexidine—ADRA2A—Platelet activation, signaling and aggregation—FGB—Parkinson's disease	0.000159	0.00356	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—HTR2A—Parkinson's disease	0.000157	0.00352	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—GRM5—Parkinson's disease	0.000157	0.00352	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—GRM4—Parkinson's disease	0.000153	0.00343	CbGpPWpGaD
Lofexidine—ADRA2A—G alpha (i) signalling events—HTR1A—Parkinson's disease	0.00015	0.00337	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.00015	0.00336	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.00015	0.00336	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.00015	0.00336	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—DGKQ—Parkinson's disease	0.000147	0.00329	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—GPR37—Parkinson's disease	0.000147	0.00329	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.000147	0.00329	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—PENK—Parkinson's disease	0.000145	0.00325	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.000142	0.00319	CbGpPWpGaD
Lofexidine—ADRA2A—G alpha (i) signalling events—DRD3—Parkinson's disease	0.00014	0.00315	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1A—Parkinson's disease	0.000139	0.00313	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADORA2A—Parkinson's disease	0.000138	0.00309	CbGpPWpGaD
Lofexidine—ADRA2A—Integration of energy metabolism—INS—Parkinson's disease	0.000136	0.00304	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD1—Parkinson's disease	0.000135	0.00302	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.000134	0.00301	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—ADORA2A—Parkinson's disease	0.000133	0.00299	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—PDYN—Parkinson's disease	0.000133	0.00297	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Parkinson's disease	0.00013	0.00292	CbGpPWpGaD
Lofexidine—ADRA2A—Hemostasis—MAG—Parkinson's disease	0.00013	0.00291	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.000129	0.00288	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.000129	0.00288	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—DGKQ—Parkinson's disease	0.000127	0.00285	CbGpPWpGaD
Lofexidine—ADRA2A—G alpha (i) signalling events—DRD2—Parkinson's disease	0.000127	0.00285	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—GRM5—Parkinson's disease	0.000123	0.00276	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—GRK5—Parkinson's disease	0.000123	0.00275	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1A—Parkinson's disease	0.000119	0.00268	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Parkinson's disease	0.000118	0.00264	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR7—Parkinson's disease	0.000118	0.00264	CbGpPWpGaD
Lofexidine—ADRA2A—Platelet activation, signaling and aggregation—SOD1—Parkinson's disease	0.000118	0.00264	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAC1—Parkinson's disease	0.000118	0.00264	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—DGKQ—Parkinson's disease	0.000115	0.00259	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—GPR37—Parkinson's disease	0.000115	0.00259	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—Parkinson's disease	0.000115	0.00259	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—TAC1—Parkinson's disease	0.000114	0.00256	CbGpPWpGaD
Lofexidine—ADRA2A—Platelet activation, signaling and aggregation—IGF2—Parkinson's disease	0.000112	0.00251	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—DRD1—Parkinson's disease	0.000112	0.00251	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Parkinson's disease	0.000112	0.00251	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—GRK5—Parkinson's disease	0.000111	0.0025	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—GRM4—Parkinson's disease	0.00011	0.00247	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—DRD3—Parkinson's disease	0.000108	0.00243	CbGpPWpGaD
Lofexidine—ADRA2A—Platelet activation, signaling and aggregation—HGF—Parkinson's disease	0.000106	0.00237	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—PPP1R1B—Parkinson's disease	0.000106	0.00237	CbGpPWpGaD
Lofexidine—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	0.000105	0.00236	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—ADORA2A—Parkinson's disease	0.000105	0.00235	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—VPS35—Parkinson's disease	0.000105	0.00235	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—PENK—Parkinson's disease	0.000104	0.00234	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	0.000103	0.00231	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR7—Parkinson's disease	0.000101	0.00227	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Parkinson's disease	0.000101	0.00227	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—GRM4—Parkinson's disease	9.98e-05	0.00224	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—DRD2—Parkinson's disease	9.79e-05	0.0022	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—HTR7—Parkinson's disease	9.79e-05	0.0022	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—GRK5—Parkinson's disease	9.63e-05	0.00216	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—PDYN—Parkinson's disease	9.53e-05	0.00214	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—PENK—Parkinson's disease	9.46e-05	0.00212	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—IL1B—Parkinson's disease	9.31e-05	0.00209	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—CASP3—Parkinson's disease	9.29e-05	0.00208	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—ND3—Parkinson's disease	9.15e-05	0.00205	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—MCCC1—Parkinson's disease	9.15e-05	0.00205	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—HTR1A—Parkinson's disease	9.09e-05	0.00204	CbGpPWpGaD
Lofexidine—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	9e-05	0.00202	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—TAC1—Parkinson's disease	8.96e-05	0.00201	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—GRM5—Parkinson's disease	8.86e-05	0.00199	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—DRD1—Parkinson's disease	8.78e-05	0.00197	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—GRK5—Parkinson's disease	8.75e-05	0.00196	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—DGKQ—Parkinson's disease	8.68e-05	0.00195	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—GPR37—Parkinson's disease	8.68e-05	0.00195	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—PDYN—Parkinson's disease	8.66e-05	0.00194	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—GRM4—Parkinson's disease	8.64e-05	0.00194	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—TALDO1—Parkinson's disease	8.6e-05	0.00193	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—OMD—Parkinson's disease	8.6e-05	0.00193	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—DRD3—Parkinson's disease	8.51e-05	0.00191	CbGpPWpGaD
Lofexidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Parkinson's disease	8.26e-05	0.00185	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—VPS35—Parkinson's disease	8.23e-05	0.00185	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—PENK—Parkinson's disease	8.19e-05	0.00184	CbGpPWpGaD
Lofexidine—ADRA2A—Hemostasis—FGB—Parkinson's disease	8.17e-05	0.00183	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—NDUFB11—Parkinson's disease	8.16e-05	0.00183	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—Parkinson's disease	8.09e-05	0.00181	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—GRM5—Parkinson's disease	8.05e-05	0.00181	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—PPP1R1B—Parkinson's disease	7.94e-05	0.00178	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—GRM4—Parkinson's disease	7.85e-05	0.00176	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—EDN1—Parkinson's disease	7.84e-05	0.00176	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—GCH1—Parkinson's disease	7.78e-05	0.00175	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—DRD2—Parkinson's disease	7.69e-05	0.00173	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—HTR7—Parkinson's disease	7.69e-05	0.00173	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—ADORA2A—Parkinson's disease	7.54e-05	0.00169	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—PDYN—Parkinson's disease	7.49e-05	0.00168	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—PENK—Parkinson's disease	7.44e-05	0.00167	CbGpPWpGaD
Lofexidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Parkinson's disease	7.07e-05	0.00159	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—GRM5—Parkinson's disease	6.97e-05	0.00156	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—RIT2—Parkinson's disease	6.94e-05	0.00156	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—FBP1—Parkinson's disease	6.93e-05	0.00156	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—DBH—Parkinson's disease	6.93e-05	0.00156	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—GBA—Parkinson's disease	6.93e-05	0.00156	CbGpPWpGaD
Lofexidine—HTR1A—GPCR ligand binding—HTR2A—Parkinson's disease	6.85e-05	0.00154	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—ADORA2A—Parkinson's disease	6.84e-05	0.00153	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—GPR37—Parkinson's disease	6.82e-05	0.00153	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—DGKQ—Parkinson's disease	6.82e-05	0.00153	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—PDYN—Parkinson's disease	6.8e-05	0.00153	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—TNF—Parkinson's disease	6.76e-05	0.00152	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—GRK5—Parkinson's disease	6.58e-05	0.00147	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—TAC1—Parkinson's disease	6.44e-05	0.00144	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—GRM5—Parkinson's disease	6.33e-05	0.00142	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—DRD1—Parkinson's disease	6.31e-05	0.00142	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—PPP1R1B—Parkinson's disease	6.24e-05	0.0014	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—EDN1—Parkinson's disease	6.16e-05	0.00138	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—DRD3—Parkinson's disease	6.12e-05	0.00137	CbGpPWpGaD
Lofexidine—ADRA2A—Hemostasis—SOD1—Parkinson's disease	6.07e-05	0.00136	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—ADORA2A—Parkinson's disease	5.92e-05	0.00133	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—GRM4—Parkinson's disease	5.9e-05	0.00132	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—TAC1—Parkinson's disease	5.85e-05	0.00131	CbGpPWpGaD
Lofexidine—ADRA2A—Hemostasis—ABL1—Parkinson's disease	5.79e-05	0.0013	CbGpPWpGaD
Lofexidine—ADRA2A—Hemostasis—IGF2—Parkinson's disease	5.76e-05	0.00129	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—DRD1—Parkinson's disease	5.73e-05	0.00129	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—ADRBK1—Parkinson's disease	5.71e-05	0.00128	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—PENK—Parkinson's disease	5.59e-05	0.00125	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—MAG—Parkinson's disease	5.59e-05	0.00125	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—DRD3—Parkinson's disease	5.55e-05	0.00125	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—HTR7—Parkinson's disease	5.53e-05	0.00124	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—DRD2—Parkinson's disease	5.53e-05	0.00124	CbGpPWpGaD
Lofexidine—HTR1A—SIDS Susceptibility Pathways—IL6—Parkinson's disease	5.45e-05	0.00122	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—RIT2—Parkinson's disease	5.45e-05	0.00122	CbGpPWpGaD
Lofexidine—ADRA2A—Hemostasis—HGF—Parkinson's disease	5.44e-05	0.00122	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR ligand binding—HTR2A—Parkinson's disease	5.39e-05	0.00121	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—ADORA2A—Parkinson's disease	5.38e-05	0.00121	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—ADRBK1—Parkinson's disease	5.19e-05	0.00116	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—GRK5—Parkinson's disease	5.17e-05	0.00116	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—HTR1A—Parkinson's disease	5.14e-05	0.00115	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—PDYN—Parkinson's disease	5.11e-05	0.00115	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—DDC—Parkinson's disease	5.09e-05	0.00114	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—TAC1—Parkinson's disease	5.06e-05	0.00114	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—HTR7—Parkinson's disease	5.02e-05	0.00113	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—DRD2—Parkinson's disease	5.02e-05	0.00113	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—DRD1—Parkinson's disease	4.96e-05	0.00111	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—GFAP—Parkinson's disease	4.81e-05	0.00108	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—DRD3—Parkinson's disease	4.81e-05	0.00108	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—GSTA4—Parkinson's disease	4.81e-05	0.00108	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—GRM5—Parkinson's disease	4.75e-05	0.00107	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—HTR1A—Parkinson's disease	4.67e-05	0.00105	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—GRM4—Parkinson's disease	4.64e-05	0.00104	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—TAC1—Parkinson's disease	4.6e-05	0.00103	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—DRD1—Parkinson's disease	4.51e-05	0.00101	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—ADRBK1—Parkinson's disease	4.49e-05	0.00101	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—EDN1—Parkinson's disease	4.43e-05	0.000993	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—PENK—Parkinson's disease	4.39e-05	0.000986	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—MAG—Parkinson's disease	4.39e-05	0.000986	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—DRD3—Parkinson's disease	4.36e-05	0.000979	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—DRD2—Parkinson's disease	4.35e-05	0.000975	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—HTR7—Parkinson's disease	4.35e-05	0.000975	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—PLA2G6—Parkinson's disease	4.33e-05	0.000971	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—MAOB—Parkinson's disease	4.28e-05	0.000961	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—FGF20—Parkinson's disease	4.17e-05	0.000935	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—ADRBK1—Parkinson's disease	4.08e-05	0.000914	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—ADORA2A—Parkinson's disease	4.04e-05	0.000907	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—EDN1—Parkinson's disease	4.02e-05	0.000902	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—PDYN—Parkinson's disease	4.02e-05	0.000902	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—DRD2—Parkinson's disease	3.95e-05	0.000885	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—HTR7—Parkinson's disease	3.95e-05	0.000885	CbGpPWpGaD
Lofexidine—HTR1A—GPCR downstream signaling—HTR2A—Parkinson's disease	3.87e-05	0.000869	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—GFAP—Parkinson's disease	3.78e-05	0.000848	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—GRM5—Parkinson's disease	3.74e-05	0.000838	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—INSR—Parkinson's disease	3.73e-05	0.000837	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—FGB—Parkinson's disease	3.53e-05	0.000791	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—HTR2A—Parkinson's disease	3.52e-05	0.000789	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—EDN1—Parkinson's disease	3.48e-05	0.000781	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—TAC1—Parkinson's disease	3.45e-05	0.000775	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—DRD1—Parkinson's disease	3.39e-05	0.00076	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—DRD3—Parkinson's disease	3.28e-05	0.000736	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—FGF20—Parkinson's disease	3.28e-05	0.000735	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—CYP2D6—Parkinson's disease	3.18e-05	0.000714	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—ADORA2A—Parkinson's disease	3.18e-05	0.000713	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—EDN1—Parkinson's disease	3.16e-05	0.000709	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—CTGF—Parkinson's disease	3.13e-05	0.000701	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—ADRBK1—Parkinson's disease	3.06e-05	0.000687	CbGpPWpGaD
Lofexidine—ADRA2A—GPCR downstream signaling—HTR2A—Parkinson's disease	3.04e-05	0.000683	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—DRD2—Parkinson's disease	2.97e-05	0.000666	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—HTR7—Parkinson's disease	2.97e-05	0.000666	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—INSR—Parkinson's disease	2.93e-05	0.000658	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—CYP2E1—Parkinson's disease	2.91e-05	0.000653	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—NQO1—Parkinson's disease	2.88e-05	0.000646	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—TH—Parkinson's disease	2.84e-05	0.000637	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—FGB—Parkinson's disease	2.77e-05	0.000622	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—HTR2A—Parkinson's disease	2.76e-05	0.00062	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—HTR1A—Parkinson's disease	2.76e-05	0.000618	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—CYCS—Parkinson's disease	2.72e-05	0.000611	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—TAC1—Parkinson's disease	2.71e-05	0.000609	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—DRD1—Parkinson's disease	2.66e-05	0.000597	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—DRD3—Parkinson's disease	2.58e-05	0.000578	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—IGF2—Parkinson's disease	2.49e-05	0.000558	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—COMT—Parkinson's disease	2.41e-05	0.000541	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—ADRBK1—Parkinson's disease	2.41e-05	0.00054	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—IGF1R—Parkinson's disease	2.4e-05	0.000539	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—GSTP1—Parkinson's disease	2.4e-05	0.000539	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—MAOA—Parkinson's disease	2.4e-05	0.000537	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—EDN1—Parkinson's disease	2.38e-05	0.000533	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—HMOX1—Parkinson's disease	2.37e-05	0.000531	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—DRD2—Parkinson's disease	2.33e-05	0.000523	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—HTR7—Parkinson's disease	2.33e-05	0.000523	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—ABCB1—Parkinson's disease	2.27e-05	0.00051	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—GSTM1—Parkinson's disease	2.21e-05	0.000495	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—NGF—Parkinson's disease	2.18e-05	0.00049	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—GPX1—Parkinson's disease	2.11e-05	0.000474	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—HTR2A—Parkinson's disease	2.08e-05	0.000466	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—IGF2—Parkinson's disease	1.95e-05	0.000438	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—MTHFR—Parkinson's disease	1.95e-05	0.000438	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—APOE—Parkinson's disease	1.93e-05	0.000433	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—IGF1R—Parkinson's disease	1.89e-05	0.000424	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—EDN1—Parkinson's disease	1.87e-05	0.000419	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—APOE—Parkinson's disease	1.82e-05	0.000407	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—NGF—Parkinson's disease	1.72e-05	0.000385	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—INS—Parkinson's disease	1.65e-05	0.00037	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—HTR2A—Parkinson's disease	1.63e-05	0.000366	CbGpPWpGaD
Lofexidine—ADRA2A—Metabolism—INS—Parkinson's disease	1.55e-05	0.000348	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—APOE—Parkinson's disease	1.52e-05	0.000341	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—INS—Parkinson's disease	1.3e-05	0.000291	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—CASP3—Parkinson's disease	1.23e-05	0.000276	CbGpPWpGaD
Lofexidine—HTR1A—Signaling by GPCR—IL6—Parkinson's disease	1.22e-05	0.000274	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—MAPK8—Parkinson's disease	1.13e-05	0.000253	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—CASP3—Parkinson's disease	9.66e-06	0.000217	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling by GPCR—IL6—Parkinson's disease	9.59e-06	0.000215	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—MAPK8—Parkinson's disease	8.88e-06	0.000199	CbGpPWpGaD
Lofexidine—HTR1A—Signaling Pathways—IL6—Parkinson's disease	7.21e-06	0.000162	CbGpPWpGaD
Lofexidine—ADRA2A—Signaling Pathways—IL6—Parkinson's disease	5.67e-06	0.000127	CbGpPWpGaD
